Corvus Pharmaceuticals, Inc.
CRVS
$4.50
-$0.13-2.81%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.03M | 1.82M | 2.18M | 1.63M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.26M | 5.94M | 6.25M | 5.63M | 5.56M |
| Operating Income | -7.26M | -5.94M | -6.25M | -5.63M | -5.56M |
| Income Before Tax | -40.22M | -4.26M | -5.70M | -6.65M | -6.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.22M | -4.26M | -5.70M | -6.65M | -6.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.22M | -4.26M | -5.70M | -6.65M | -6.00M |
| EBIT | -7.26M | -5.94M | -6.25M | -5.63M | -5.56M |
| EBITDA | -7.23M | -5.91M | -6.23M | -5.60M | -5.53M |
| EPS Basic | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 |
| Normalized Basic EPS | -0.38 | -0.04 | -0.07 | -0.08 | -0.08 |
| EPS Diluted | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 |
| Normalized Diluted EPS | -0.38 | -0.04 | -0.07 | -0.08 | -0.08 |
| Average Basic Shares Outstanding | 66.70M | 59.71M | 49.04M | 49.04M | 48.97M |
| Average Diluted Shares Outstanding | 66.70M | 59.71M | 49.04M | 49.04M | 48.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
